259 related articles for article (PubMed ID: 25638544)
1. Galeterone activity in castration-resistant prostate cancer.
Yaqub F
Lancet Oncol; 2015 Jan; 16(1):e10. PubMed ID: 25638544
[No Abstract] [Full Text] [Related]
2. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
Crona DJ; Milowsky MI; Whang YE
Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358
[TBL] [Abstract][Full Text] [Related]
3. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
[TBL] [Abstract][Full Text] [Related]
4. [New generation of androgen receptor antagonist in castration resistant prostate cancer].
Uemura H
Nihon Rinsho; 2014 Dec; 72(12):2164-9. PubMed ID: 25518352
[TBL] [Abstract][Full Text] [Related]
5. Targeting the androgen receptor in metastatic castration-resistant prostate cancer.
Aragon-Ching JB
Future Oncol; 2014 Feb; 10(3):329-32. PubMed ID: 24559439
[No Abstract] [Full Text] [Related]
6. Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer.
Montgomery B; Eisenberger MA; Rettig MB; Chu F; Pili R; Stephenson JJ; Vogelzang NJ; Koletsky AJ; Nordquist LT; Edenfield WJ; Mamlouk K; Ferrante KJ; Taplin ME
Clin Cancer Res; 2016 Mar; 22(6):1356-63. PubMed ID: 26527750
[TBL] [Abstract][Full Text] [Related]
7. Strategies for targeting the androgen receptor axis in prostate cancer.
Carver BS
Drug Discov Today; 2014 Sep; 19(9):1493-7. PubMed ID: 25107669
[TBL] [Abstract][Full Text] [Related]
8. Androgen deprivation of prostate cancer: Leading to a therapeutic dead end.
Katzenwadel A; Wolf P
Cancer Lett; 2015 Oct; 367(1):12-7. PubMed ID: 26185001
[TBL] [Abstract][Full Text] [Related]
9. Update on systemic therapy for advance prostate cancer.
Carthon B; Rossi PJ
Curr Probl Cancer; 2015; 39(1):52-62. PubMed ID: 25637932
[No Abstract] [Full Text] [Related]
10. Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer.
Dellis A; Papatsoris AG
Expert Opin Investig Drugs; 2016 Jun; 25(6):697-707. PubMed ID: 26954621
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptors in early and castration resistant prostate cancer: friend or foe?
Pelekanou V; Notas G; Stathopoulos EN; Castanas E; Kampa M
Hormones (Athens); 2013; 12(2):224-35. PubMed ID: 23933691
[No Abstract] [Full Text] [Related]
12. Leading causes of castration-resistant prostate cancer.
Lu M; Lu H; Kong Q
Expert Rev Anticancer Ther; 2015 Apr; 15(4):425-32. PubMed ID: 25645203
[TBL] [Abstract][Full Text] [Related]
13. Clinical and molecular features of treatment-related neuroendocrine prostate cancer.
Akamatsu S; Inoue T; Ogawa O; Gleave ME
Int J Urol; 2018 Apr; 25(4):345-351. PubMed ID: 29396873
[TBL] [Abstract][Full Text] [Related]
14. Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer.
Sharp A; Welti J; Blagg J; de Bono JS
Clin Cancer Res; 2016 Sep; 22(17):4280-2. PubMed ID: 27330057
[TBL] [Abstract][Full Text] [Related]
15. The biology of castration-resistant prostate cancer.
Lian F; Sharma NV; Moran JD; Moreno CS
Curr Probl Cancer; 2015; 39(1):17-28. PubMed ID: 25547388
[No Abstract] [Full Text] [Related]
16. [Qualitative and quantitative hormonal regulation in castration-resistant prostate cancer].
Murez T; Basset V; Audenet F; Lebret T; Branchereau J
Prog Urol; 2013 Oct; 23 Suppl 1():S1-8. PubMed ID: 24314734
[TBL] [Abstract][Full Text] [Related]
17. Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC).
Tsao CK; Galsky MD; Small AC; Yee T; Oh WK
BJU Int; 2012 Dec; 110(11):1580-8. PubMed ID: 22985411
[TBL] [Abstract][Full Text] [Related]
18. [New therapies in metastatic castration resistant prostate cancer].
Thibault C; Massard C
Bull Cancer; 2015 Jun; 102(6):501-8. PubMed ID: 26022286
[TBL] [Abstract][Full Text] [Related]
19. [ASC-J9 for castration-resistant prostate cancer].
Yamashita S; Arai Y
Nihon Rinsho; 2014 Dec; 72(12):2126-9. PubMed ID: 25518345
[TBL] [Abstract][Full Text] [Related]
20. Novel drugs targeting the androgen receptor pathway in prostate cancer.
Mateo J; Smith A; Ong M; de Bono JS
Cancer Metastasis Rev; 2014 Sep; 33(2-3):567-79. PubMed ID: 24390422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]